Cellectis: Four Prominent Physicians to Join Cellectis Clinical Advisory Board

NEW YORK–(BUSINESS WIRE)– class= »bwalignl »>
Regulatory News:

Cellectis
(Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a
biopharmaceutical company focused on developing immunotherapies based on
gene edited CAR T-cells (UCART), today announced that four new members
joined Cellectis’ Clinical Advisory Board (CAB). The CAB serves as a
strategic resource to Cellectis as the Company enters the clinical
development of allogeneic CAR T immunotherapies lead by its wholly owned
product candidate, UCART123.

The CAB initially comprises Pr John Gribben, Lead of the Centre for
Hemato-Oncology, Barts Cancer Institute of London, UK; Pr Koen van
Besien, Director of the Stem Cell Transplant Program and Professor of
Medicine at Weill Cornell Medical College, NYC, USA; Pr Kanti Rai,
Professor of Medicine and Molecular Medicine, Hofstra Northwell School
of Medicine, Hempstead, USA and Pr Catherine Thieblemont, Professor of
Hematology in the Paris VII- University, France and Head of the
Hemato-Oncology Unit of St-Louis Hospital in Paris.

« We are honored that these leaders have agreed to join Cellectis’
Clinical Advisory Board as forward-thinking experts, innovators and
visionaries in their respective fields,” said Dr. Loan Hoang-Sayag,
Chief Medical Officer, Cellectis. “Professors Gribben, van Besien, Rai
and Thieblemont are strong supporters of Cellectis’ allogeneic,
‘off-the-shelf’ approach to developing immunotherapies. The in-depth
experience of these leading physicians across the hematologic
malignancies / stem cell transplant, immunotherapy and
hematology-oncology clinical research fields will greatly inform our
ongoing work to address the unmet needs of different patient populations
globally.”

Professor Gribben holds the Gordon Hamilton Fairley Chair of Medical
Oncology at St. Bartholomew’s Hospital, Barts Cancer Institute, Queen
Mary, University of London, where his research group is currently
focused on immunological approaches to the treatment of hematological
cancers. He was a research fellow at University College London and
Dana-Farber Cancer Institute, Harvard Medical School. He joined the
faculty at Harvard Medical School, the Dana-Farber Cancer Institute and
Brigham and Women’s Hospital in 1992. He is a founding member of the CLL
Research Consortium, was Associate Editor of Blood from 2008-2014
and was elected a Fellow of the Academy of Medical Science. He will be
President–Elect of The European Hematology Association (EHA) from 2017
to 2019.

Professor van Besien serves as Director of the Stem Cell Transplant
Program at Weill Cornell Medical Center and is an Attending Physician at
New York Presbyterian Hospital. A graduate of the College ND de la Paix
in Namur, Belgium, and University of Leuven, Belgium. Professor van
Besien also holds a PhD from the University of Maastricht in the
Netherlands. He completed a hematology/oncology fellowship at Indiana
University and in Bruges, Belgium, and was a faculty member of the
transplant program at MD Anderson Cancer Center. The Professor also
directed the transplant program at the University of Illinois and the
transplant and lymphoma programs at the University of Chicago. He is
Editor-in-chief of Leukemia and Lymphoma.

Professor Rai, an internationally renowned leukemia researcher and
hematologist, brings extensive knowledge and experience from his 50-year
career spanning groundbreaking clinical leukemia research. He is the
Joel Finkelstein Cancer Foundation Professor of Medicine at the Hofstra
North Shore-LIJ School of Medicine, where he is also Professor of
Molecular Medicine. He is currently Chief of the Chronic Lymphocytic
Leukemia (CLL) Research and Treatment Program at Northwell Cancer
Institute and an Investigator at The Feinstein Institute for Medical
Research.

Professor Thieblemont is Professor of Hematology in the Paris VII-
University, France, and Head of the Hemato-Oncology Department in
the Hospital Saint-Louis – Paris, France, where she develops specific
therapeutic programs for refractory/relapsed lymphomas and chronic
lymphocytic leukemia. She belongs to the administrative and scientific
committees of the LYSA, the lymphoma study association, to the board of
directors of the IELSG, the International extranodal lymphoma study
association, and to the Fellowships and Grants Committee of The European
Hematology Association (EHA).

“As Cellectis is expected to start the world’s first clinical trial to
ever use an allogeneic CAR T therapy in the U.S., the Company’s Clinical
Advisory Board will greatly guide us in moving full steam ahead,” added
Dr. Hoang-Sayag. “The goal is that the allogeneic CAR T cell approach
will lead to a drug that is cost-effective, easily distributed across
all geographies and immediately available to patients in need. We are
thrilled to have Professors Gribben, van Besien, Rai and Thieblemont
onboard as we inch closer to reaching this monumental milestone for
cancer patients everywhere and revolutionizing cancer treatment as we
know it today.”

About Cellectis

Cellectis is a biopharmaceutical company focused on developing
immunotherapies based on gene edited CAR T-cells (UCART). The company’s
mission is to develop a new generation of cancer therapies based on
engineered T-cells. Cellectis capitalizes on its 17 years of expertise
in genome engineering – based on its flagship TALEN® products and
meganucleases and pioneering electroporation PulseAgile technology – to
create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the Nasdaq market
(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find
out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark
owned by the Cellectis Group.

Disclaimer

This press release contains “forward-looking” statements that are based
on our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. The
risks and uncertainties include, but are not limited to, the risk that
the preliminary results from our product candidates will not continue or
be repeated, the risk of not obtaining regulatory approval to commence
clinical trials on the UCART product candidates, the risk that any one
or more of our product candidates will not be successfully developed and
commercialized. Further information on the risks factors that may affect
company business and financial performance, is included in filings
Cellectis makes with the Security Exchange Commission from time to time
and its financial reports. Except as required by law, we assume no
obligation to update these forward-looking statements publicly, or to
update the reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new information
becomes available in the future.

# # #

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170123006009/en/